Radiation therapy advancement declared by GT Medical Technologies
In a significant development for the treatment of brain tumors, the bioabsorbable collagen implant known as GammaTile has been adopted by over 200 cancer centers, hospitals, and institutions across the United States.
Developed by Tempe, AZ-based company GT Medical Technologies, GammaTile was first used on a patient with a newly diagnosed brain tumor at Jersey Shore University Medical Center in Neptune City, NJ, in January 2020. Since then, the number of cancer centers, hospitals, and institutions using GammaTile in the U.S. has exceeded 200.
The U.S. Food and Drug Administration (FDA) cleared GammaTile for use in both newly diagnosed and recurrent brain tumors. In 2018, the FDA cleared GammaTile for use in recurrent brain tumors, and in 2020, the FDA expanded its clearance to include newly diagnosed brain tumors.
GammaTile is placed at the time of tumor removal surgery and is a bioabsorbable collagen implant embedded with radiation seeds. The implant delivers targeted radiation to the tumor site when cancer cells are at their lowest levels, providing an additional layer of treatment and potentially improving outcomes for patients.
GT Medical Technologies has reported a high adoption rate for GammaTile among cancer centers, hospitals, and institutions in the U.S. since its full market launch in March 2020. The company announced that GammaTile has been adopted by more than 200 cancer centers, hospitals, and institutions in the U.S., marking a significant milestone in the adoption of this innovative treatment.
The widespread adoption of GammaTile is a testament to its potential to improve outcomes for patients with operable brain tumors. The 2,000th patient was treated with the GammaTile implant at Jersey Shore University Medical Center in Neptune City, NJ, demonstrating the growing acceptance and use of this technology in the treatment of brain tumors.
As the number of cancer centers, hospitals, and institutions adopting GammaTile continues to grow, it is clear that this technology is making a meaningful impact in the fight against brain cancer. The future of GammaTile and its potential to transform the treatment of brain tumors is promising, and we can expect to see even more widespread adoption in the coming years.
